Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients

Journal of Hepatology

Volumn 28, Issue 6, 1998, Pages 951-959

  Brouwer, Johannes T ^a   Nevens, Frederik ^c   Kleter, Bernhard ^a   Elewaut, Andre ^d   Alder, Michael ^e   Brenard, Reginald ^f   Chamuleau, Rob A F M ^b   Michielsen, Peter P ^g   Pirotte, Jean ^h   Hautekeete, Marc L ⁱ   Weber, Joseph ^j   Bourgeois, Nadine ^e   Hansen, Bettina E ^a   Bronkhorst, Carolien M ^b   Ten Kate, Fibo J W ^b   Heijtink, Rudolf A ^a   Fevery, Johan ^c   Schalm, Solko W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e ERASME HOSPITAL   (Belgium)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h UNIVERSITY OF LIÈGE   (Belgium)

ⁱ FREE UNIVERSITY OF BRUSSELS   (Belgium)

^j Central Hospital   (Luxembourg)

more..

Author keywords

Alanine aminotransferase; Dose response; Genotype; HCV RNA; Hepatitis C; Interferon alpha 2b; Multicenter studies; Multivariate analysis; Randomized controlled trials; Treatment outcome

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 7144227276     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80342-5     Document Type: Article

References (36)

1. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 315:1986;1575-1578.
2. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr., Perrillo RP. . Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial N Engl J Med. 321:1989;1501-1506.
3. Di Bisceglie AM, Martin P, Kassianides C, Lisker Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
4. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. . Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial J Hepatol. 23:1995;487-496.
5. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
6. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 35:1977;1-39.
7. Kleter GE, van Doorn LJ, Brouwer JT, Schalm SW, Heijtink RA, Quint WG. Sequence analysis of the 5′ untranslated region in isolates of at least four genotypes of hepatitis C virus in The Netherlands. J Clin Microbiol. 32:1994;306-310.
8. Zaaijer HL, Cuypers HT, Reesink HW, Winkel IN, Gerken G, Lelie PN. Reliability of polymerase chain reaction for detection of hepatitis C virus. Lancet. 341:1993;722-724.
9. Kleter GE, van Doorn LJ, Stuyver L, Maertens G, Brouwer JT, Schalm SW, et al. Rapid genotyping of hepatitis C virus RNA-isolates obtained from patients residing in western Europe. J Med Virol. 47:1995;35-42.
10. Hawkins A, Davidson F, Simmonds P, Comparison of, plasma virus loads among individuals infected with hepatitis, C virus (HCV) genotypes 12 and 3 by quantiplex HCV RNA, assay versions 1 and 2 Roche Monitor assay and an inhouse, limiting dilution method. J Clin Microbiol. 35:1997;187-192.
11. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic activite hepatitis. Hepatology. 1:1981;431-435.
12. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1994;1513-1520.
13. Anonymous. National Institutes of Health Consensus Development conference Panel statement: management of hepatitis C. Hepatology. 26:1997;2-10. (Suppl 1).
14. Lindsay KL. Therapy of hepatitis C: overview. Hepatology. 26:1997;71-77. (Suppl 1).
15. Kleter GE, Brouwer JT, Heijtink RA, Schalm SW, Quint WG. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrob Agents Chemother. 37:1993;595-597.
16. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL. . Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial Hepatology. 24:1996;1034-1040.
17. Bellobuono A, Mondazzi L, Tempini S, Bellati G, Ideo G. . Comparison between fixed and escalating doses of alpha interferon treatment in chronic hepatitis C [abstract] Hepatology. 22:1995;152.
18. Chemello L, Bonetti P, Cavelletto L, Talato F, Donadon V, Casarin P. . Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C Hepatology. 22:1995;700-706.
19. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N. . Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C Gastroenterology. 109:1995;156-165.
20. Jouet P, Roudot-Thoraval F, Dhumeaux D, Metreau JM. . Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis Gastroenterology. 106:1994;686-690.
21. Craxi A, Dimarco V, Loiacono O, Almasio P, Bruno R, Camma C, et al. Transfusion-associated chronic hepatitis C; alpha-n(1) interferon for 6 vs 12 months. J Hepatol. 24:1996;539-546.
22. Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ, Contos MJ, Mills AS. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose. Hepatology. 24:1996;21-26.
23. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology. 21:1995;291-297.
24. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 24:1996;778-789.
25. Lau JY, Davis GL, Kniffen J, Qian KP, Urdea MS, Chan CS, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet. 341:1993;1501-1504.
26. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol. 21:1994;1-3.
27. Davis Gl, Lindsay K, Albrecht J, Bodenheimer HC Jr., Balart LA, Perillo RP, et al. Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J Viral Hepat. 1:1994;55-63.
28. Pagliaro L, Craxi A, Cammaa C, Tine F, Di Marco V, Lo Iacono O, et al. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology. 19:1994;820-828.
29. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content in the liver. J Hepatol. 20:1994;410-415.
30. Chemello L, Cavalletto L, Noventa F, Bonetti P, Casarin C, Bernardinello E, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. J Viral Hepat. 2:1995;91-96.
31. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology. 22:1995;1050-1056.
32. Pawlotsky JM, Roudot-Thoraval F, Bastie A, Darthuy F, Remire J, Metreau JM, et al. Factors affecting treatment responses to interferon-alpha in chronic hepatitis C. J Infect Dis. 174:1996;1-7.
33. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 95:1988;734-739.
34. Brouwer JT, Nevens F, Michielsen P, Hautekeete ML, Chamuleau RAFM, Adler M, et al. What options are left when hepatitis C does not respond to interferon? Placebo controlled Benelux multicentre retreatment trial on Ribavirin monotherapy versus combination with interferon. J Hepatol. 21:1994;17. (suppl 1).
35. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the toxicity of interferon in chronic hepatitis C. Meta-analysis of individual European patients. J Hepatol. 26:1997;961-966.
36. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci. 38:1993;612-618.